Literature DB >> 9859961

Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy.

J Izopet1, G Salama, C Pasquier, K Sandres, B Marchou, P Massip, J Puel.   

Abstract

We have examined the effect of potent antiretroviral regimens on the latent reservoirs of HIV-1. The HIV-1 DNA in the peripheral blood mononuclear cells (PBMC) of 10 patients with undetectable plasma HIV-1 RNA (<20 copies/ml) who had received combination antiretroviral therapy was assayed every 12 weeks. No evidence of residual viral replication was found in the PBMC after 24 weeks of treatment. Although HIV-1 DNA remained detectable in all patients, it decreased significantly from 3.5 log copies/10(6) cells (range, 1.8-4.7 log copies/10(6) cells) to 2.3 log copies/10(6) cells (range, 0.6-3.1 log copies/10(6) cells) after 60 weeks of suppressive therapy. Analysis based on 6 patients who reached 60 weeks showed a slow decline with an estimated half-life of 40 weeks (range, 26-163 weeks). Genotypic analysis by sequencing the HIV-1 pol gene revealed no changes in the reverse transcriptase or protease coding regions after 48 to 60 weeks of therapy. The findings suggest that, in addition to potent antiretroviral regimens, new strategies must be developed to ensure eradication of the latent reservoir of provirus, and hence of the virus itself.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9859961     DOI: 10.1097/00042560-199812150-00006

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  9 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV.

Authors:  Jérôme Legoff; Hicham Bouhlal; Gérard Grésenguet; Helen Weiss; Nzambi Khonde; Hakim Hocini; Nathalie Désiré; Ali Si-Mohamed; Jean de Dieu Longo; Cécile Chemin; Eric Frost; Jacques Pépin; Jean-Elie Malkin; Philippe Mayaud; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

3.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Retrospective analysis of the HIV-1 reverse transcriptase inhibitors' resistance in Silesia, Poland.

Authors:  Joanna Smolén; Piotr Kruszyński; Jolanta Bratosiewicz-Wąsik; Adam Witor; Tomasz J Wąsik
Journal:  Med Sci Monit       Date:  2011-02

6.  Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

Authors:  Dai Watanabe; Shiro Ibe; Tomoko Uehira; Rumi Minami; Atsushi Sasakawa; Keishiro Yajima; Hitoshi Yonemoto; Hiroki Bando; Yoshihiko Ogawa; Tomohiro Taniguchi; Daisuke Kasai; Yasuharu Nishida; Masahiro Yamamoto; Tsuguhiro Kaneda; Takuma Shirasaka
Journal:  BMC Infect Dis       Date:  2011-05-24       Impact factor: 3.090

7.  Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.

Authors:  Rajesh T Gandhi; Deborah K McMahon; Ronald J Bosch; Christina M Lalama; Joshua C Cyktor; Bernard J Macatangay; Charles R Rinaldo; Sharon A Riddler; Evelyn Hogg; Catherine Godfrey; Ann C Collier; Joseph J Eron; John W Mellors
Journal:  PLoS Pathog       Date:  2017-04-20       Impact factor: 6.823

8.  Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland.

Authors:  Joanna Smoleń-Dzirba; Magdalena Rosińska; Piotr Kruszyński; Jolanta Bratosiewicz-Wąsik; Robert Wojtyczka; Janusz Janiec; Bartosz Szetela; Marek Beniowski; Monika Bociąga-Jasik; Elżbieta Jabłonowska; Tomasz J Wąsik; And The Cascade Collaboration In EuroCoord
Journal:  Med Sci Monit       Date:  2017-02-07

9.  Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.

Authors:  Gabriella Rozera; Gabriele Fabbri; Patrizia Lorenzini; Ilaria Mastrorosa; Laura Timelli; Mauro Zaccarelli; Alessandra Amendola; Alessandra Vergori; Maria Maddalena Plazzi; Stefania Cicalini; Andrea Antinori; Maria Rosaria Capobianchi; Isabella Abbate; Adriana Ammassari
Journal:  PLoS One       Date:  2017-10-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.